Cemiplimab vs best care for advanced vulvar cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests if the immunotherapy drug cemiplimab can help keep advanced or recurrent vulvar cancer from growing after initial chemotherapy. Patients who have finished 4-6 cycles of platinum chemo without their cancer getting worse may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older.
- You have vulvar squamous cell cancer that is advanced, recurrent, or has spread and cannot be cured with standard treatments.
- You have completed 4 to 6 cycles of platinum-based chemotherapy as your first treatment and your cancer did not get worse (it may have shrunk or stayed the same).
- Your doctor has determined your overall health is good enough for daily activities (ECOG score 0, 1, or 2).
- You have not had prior immunotherapy (like PD-1 or CTLA-4 inhibitors) or an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a maintenance drug called cemiplimab (an immunotherapy) can help keep your penile cancer from growing after you've finished platinum-based chemotherapy. It's a randomized study, so half the participants get cemiplimab and the other half get the best standard care, so doctors can compare which works better.
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.
This trial tests combining two drugs, nivolumab (an immunotherapy) and imiquimod (a cream that boosts the immune system), to treat vulvar squamous cell carcinoma. It aims to shrink tumors before surgery and may be an option for women with large or multifocal tumors.
This study tests a combination of an immunotherapy drug (cemiplimab) plus chemotherapy for advanced squamous non-small cell lung cancer. Researchers want to see if this treatment works better in people whose tumors have a certain enzyme level.
Hear when a new Vulvar Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.